In acute myeloid leukemia (AML), both cytogenetic and molecular abnormalities are strongly associated with prognosis. In particular, in cytogenetically normal AML.Families of myeloproliferative neoplasms (MPNs) are characterized by a clinical and genetic heterogenceity. First, within MPN families, distinct clinical entities are observed, the 3 main ones being polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).Recently, acquired mutations of the Ten-Eleven Translocation 2 gene, (TET2), were reported in approximately 12% of sporadic MPN (PV, ET, and PMF) as well as in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).